| Dokumendiregister | Ravimiamet |
| Viit | REP-1/1892-1 |
| Registreeritud | 23.05.2024 |
| Sünkroonitud | 24.05.2024 |
| Liik | Sissetulev kiri |
| Funktsioon | REP Euroopa Farmakopöaga seotud asjaajamine |
| Sari | REP-1 Euroopa Farmakopöa alane kirjavahetus |
| Toimik | REP-1/2024 |
| Juurdepääsupiirang | Avalik |
| Juurdepääsupiirang | |
| Adressaat | European Directorate for the Quality of Medicines & HealthCare |
| Saabumis/saatmisviis | European Directorate for the Quality of Medicines & HealthCare |
| Vastutaja | Signe Leito (RA, Labor) |
| Originaal | Ava uues aknas |
1
Signe Leito
Saatja: [email protected] Saatmisaeg: teisipäev, 14. mai 2024 18:32 Adressaat: Signe Leito Teema: Proposed addition to the PaedF WP: Warfarin oral liquid: EDQM-2024-02007-mail
Please make sure to include in any reply our mail reference: EDQM-2024-02007-mail **************************************************************************** For the attention of NPAs Copy: Presidium Dear Colleagues, Please find below the link to a survey being carried out concerning the proposed addition of Warfarin oral liquid to the work programme of the European Paediatric Formulary. In order to have access to the survey, please copy and paste this link into your Internet browser: https://survey.edqm.eu/index.php?r=survey/index&sid=542951&lang=en Deadline for replies: 4 June 2024 With kind regards, On behalf of Jane Francomb Bénédicte Bunner Administrative Support Assistant European Pharmacopoeia Department (EPD) European Directorate for the Quality of Medicines & HealthCare (EDQM) Council of Europe - Conseil de l'Europe
Tähelepanu! Tegemist on väljastpoolt asutust saabunud kirjaga. Tundmatu saatja korral palume linke ja faile mitte avada.
2
To reach us, we invite you to contact us electronically. You can also contact us via HelpDesk https://www.edqm.eu / https://www.edqm.eu/store Stay connected with the EDQM
Confidentiality Notice: This e-mail and any attached files may contain confidential information that is intended only for the addressee(s). If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or reliance upon the contents of this e-mail (including any attached files) is strictly prohibited. Anyone who receives this message in error should notify the sender immediately by using the reply function and then permanently delete this e-mail (including any attached files). Thank you.
**************************************************************************** Please make sure to include in any reply our mail reference: EDQM-2024-02007-mail